Evaluating the effect of ursodeoxycholic acid on early hepatic clearance of 99mTc-sestamibi radiomaterial in patients undergoing myocardial perfusion scintigraphy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230704058666N1

Enrollment

168

Registered

2025-07-08

Start date

2025-08-23

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IHD. Other forms of acute ischemic heart disease

Interventions

Intervention 1: Experimental Intervention Specifications Drug Name: Ursodeoxycholic Acid (UDCA)Brand Name: Ursodex 300Manufacturer: EXIR Pharma Co., Iran Dosage Form: 300 mg capsuleChemical Compositio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: indication for myocardial perfusion scintigraphy

Exclusion criteria

Exclusion criteria: no prior hepatic disease

Design outcomes

Primary

Measure	Time frame
Faster tracer washout from the liver. Timepoint: 60 minutes after tracer injection. Method of measurement: heart to background and liver ratio in cardiac software.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactmohammadali Ghodsirad

Shahid Beheshti University of Medical Sciences

Gho.rad81@gmail.com+98 21 2272 3263

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026